Newsletter Tool

Today's Rundown

Sayonara, San Francisco. #JPM22 is going virtual, thanks to COVID
Sanofi, GSK push COVID-19 vaccine data into 2022. Will strong booster data hold their place in line?
Humana, Centene sue pharma companies over alleged scheme to squash HIV drug competition
Medtronic receives FDA warning letter over quality control issues at diabetes HQ
After Roche bails, Atea will try to pair failed COVID-19 drug with other compounds
AbbVie's Rinvoq, Pfizer's Xeljanz win new uses after extended reviews as JAK safety woes linger
Big data startup Innovaccer nabs $150M, catapults to $3.2B valuation
NuVasive resumes global sales of scoliosis system with reinstated CE mark and new labeling
Eli Lilly trots out rosy 2022 projections, sees recent launches driving two-thirds of its business
Lilly packs up ulcerative colitis med for FDA with phase 3 success after ditching psoriasis
UK antitrust watchdog investigates Microsoft-Nuance deal following EU probe
Biopharma charts progress in translating CAR-T cell therapies to solid cancers
Route 92 Medical collects $111M for its brain blood clot-clearing devices

Featured Story

Sayonara, San Francisco. #JPM22 is going virtual, thanks to COVID

By Eric Sagonowsky

Cancelled flights and hotel rooms have become par for the course during the COVID-19 pandemic. Now, with less than a month to go until the J.P. Morgan healthcare conference in January, the event organizers have pivoted to a virtual event, triggering another round of cancelled travel plans.

Sanofi, GSK push COVID-19 vaccine data into 2022. Will strong booster data hold their place in line?

By Annalee Armstrong

Sanofi and GlaxoSmithKline are delaying booster data for their combined COVID-19 vaccine into the first quarter of 2022, a readout that has been eagerly anticipated by investors and analysts.

Humana, Centene sue pharma companies over alleged scheme to squash HIV drug competition

By Paige Minemyer

Humana, Centene and several Blues plans have filed suit against multiple drugmakers, charging that the companies illegally conspired to protect market exclusivity for widely-prescribed HIV drugs.

Medtronic receives FDA warning letter over quality control issues at diabetes HQ

By Andrea Park

The warning letter was the result of an inspection of the Southern California facility that the FDA completed in July, related to a pair of Class I recalls issued for several models of Medtronic’s MiniMed insulin pumps.

After Roche bails, Atea will try to pair failed COVID-19 drug with other compounds

By Annalee Armstrong

After getting ditched by Roche a month ago, Atea is laying out a path forward for a failed COVID-19 med called AT-527, including a plan to conduct combination studies. Back in November, Roche cut ties on a $350 million deal with the small biotech after the drug failed to live up to expectations in the clinic.

AbbVie's Rinvoq, Pfizer's Xeljanz win new uses after extended reviews as JAK safety woes linger

By Angus Liu

After the FDA finalized its review of safety risks for oral JAK inhibitors, it's now ready to sign off on several inflammatory disease applications that had been delayed—only with unfavorable use restrictions.

Big data startup Innovaccer nabs $150M, catapults to $3.2B valuation

By Rebecca Torrence

Innovaccer landed $150 million in a series E funding round that boosted the big data healthcare startup to a $3.2 billion valuation. Innovaccer's Health Cloud has seen rapid adoption since its February launch, and the startup now has more than 50 clients and growing.

NuVasive resumes global sales of scoliosis system with reinstated CE mark and new labeling

By Andrea Park

The stars are aligning for NuVasive and its MAGEC spine-straightening system.

Eli Lilly trots out rosy 2022 projections, sees recent launches driving two-thirds of its business

By Kevin Dunleavy

Eli Lilly said happy holidays to its stakeholders on Wednesday morning, bumping up its projections for revenue for this year and next, along with providing a comprehensive overview of its present and future.

Lilly packs up ulcerative colitis med for FDA with phase 3 success after ditching psoriasis

By Kyle LaHucik

Eli Lilly will ask the FDA to approve its IL-23 drug mirikizumab in ulcerative colitis next year after passing a phase 3 test in the inflammatory bowel disease.

UK antitrust watchdog investigates Microsoft-Nuance deal following EU probe

By Rebecca Torrence

The U.K.’s antitrust regulatory body has opened an investigation into Microsoft’s acquisition of speech technology company Nuance Communications, one week after news broke of an EU antitrust probe into the deal.

Biopharma charts progress in translating CAR-T cell therapies to solid cancers

By Arlene Weintraub

Several startups are raising interest—and dollars—to support innovative strategies for developing cell therapies to treat solid tumors. But their task is far from easy, with a combination of logistical hurdles and safety issues threatening to slow their progress.

Route 92 Medical collects $111M for its brain blood clot-clearing devices

By Conor Hale

The stealthy California developer of a catheter-based blood clot removal system for stroke has secured $111 million to help complete its clinical testing and carry its device through the FDA.

PM Tracker